261 related articles for article (PubMed ID: 28025101)
41. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
[TBL] [Abstract][Full Text] [Related]
42. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF
Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602
[TBL] [Abstract][Full Text] [Related]
43. Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
Möckelmann N; Rieckmann T; Busch CJ; Becker B; Gleißner L; Hoffer K; Omniczynski M; Steinmeister L; Laban S; Grénman R; Petersen C; Rothkamm K; Dikomey E; Knecht R; Kriegs M
Oncotarget; 2016 Apr; 7(17):23542-51. PubMed ID: 27015558
[TBL] [Abstract][Full Text] [Related]
44. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.
Beyer C; Zenzmaier C; Palumbo-Zerr K; Mancuso R; Distler A; Dees C; Zerr P; Huang J; Maier C; Pachowsky ML; Friebe A; Sandner P; Distler O; Schett G; Berger P; Distler JH
Ann Rheum Dis; 2015 Jul; 74(7):1408-16. PubMed ID: 24567525
[TBL] [Abstract][Full Text] [Related]
45. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
46. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
47. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
Beyer C; Reich N; Schindler SC; Akhmetshina A; Dees C; Tomcik M; Hirth-Dietrich C; von Degenfeld G; Sandner P; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 Jun; 71(6):1019-26. PubMed ID: 22294631
[TBL] [Abstract][Full Text] [Related]
48. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma.
Gu F; Ma Y; Zhang Z; Zhao J; Kobayashi H; Zhang L; Fu L
Oncol Rep; 2010 Mar; 23(3):671-6. PubMed ID: 20127005
[TBL] [Abstract][Full Text] [Related]
49. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence.
Stasch JP; Schlossmann J; Hocher B
Curr Opin Pharmacol; 2015 Apr; 21():95-104. PubMed ID: 25645316
[TBL] [Abstract][Full Text] [Related]
50. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
Bauer JA; Kumar B; Cordell KG; Prince ME; Tran HH; Wolf GT; Chepeha DB; Teknos TN; Wang S; Eisbruch A; Tsien CI; Urba SG; Worden FP; Lee J; Griffith KA; Taylor JM; D'Silva N; Wang SJ; Wolter KG; Henson B; Fisher SG; Carey TE; Bradford CR
Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S106-8. PubMed ID: 17848273
[TBL] [Abstract][Full Text] [Related]
51. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
52. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
[TBL] [Abstract][Full Text] [Related]
53. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
[TBL] [Abstract][Full Text] [Related]
54. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
[TBL] [Abstract][Full Text] [Related]
55. Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
Stoehr M; Mozet C; Boehm A; Aigner A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2014 Apr; 73(4):827-37. PubMed ID: 24562588
[TBL] [Abstract][Full Text] [Related]
56. Intrinsic differences in cisplatin sensitivity of head and neck cancer cell lines: Correlation to lysosomal pH.
Nilsson C; Roberg K; Grafström RC; Ollinger K
Head Neck; 2010 Sep; 32(9):1185-94. PubMed ID: 20029982
[TBL] [Abstract][Full Text] [Related]
57. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Stasch JP; Hobbs AJ
Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
[TBL] [Abstract][Full Text] [Related]
58. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation.
Nimmegeers S; Sips P; Buys E; Brouckaert P; Van de Voorde J
Cardiovasc Res; 2007 Oct; 76(1):149-59. PubMed ID: 17610859
[TBL] [Abstract][Full Text] [Related]
59. Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells.
Kim JS; Lee JH; Jeong WW; Choi DH; Cha HJ; Kim DH; Kwon JK; Park SE; Park JH; Cho HR; Lee SH; Park SK; Lee BJ; Min YJ; Park JW
Int J Cancer; 2008 Feb; 122(3):672-80. PubMed ID: 17955488
[TBL] [Abstract][Full Text] [Related]
60. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
